Navigation Links
Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association

HARBIN, China, May 5 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company was recently elected as a Deputy Chair of Heilongjiang Medical Association ("the Association") by members of the Association.

Established in 2006, the Association is an industry-supported, non-profit organization with over 130 member institutions, including pharmaceutical companies, other healthcare firms and scientific research organizations. Its purpose is to promote the advancement of medical research and support the development of healthcare-related industries in Heilongjiang province. The Association plays an important role in facilitating communication between members and other relevant institutions, such as Heilongjiang's Food and Drug Administration, apprising members of industry trends and guiding members on technological advancements and other innovations. The Association also assists the local and provincial government in evaluating important scientific and technological projects and setting relevant policies. As a Deputy Chair of the Association, Renhuang will play a leading role in guiding the organization's development, helping to shape the future of Heilongjiang's healthcare industry and influence the industry's working relationship with the local and regional government.

"We are honored to be elected as the Deputy Chair Unit of the Association and support its mission to develop Heilongjiang's pharmaceutical industry," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "We believe Renhuang's election is a recognition of the Company's leadership in the pharmaceutical industry and, as the Deputy Chair Unit, look forward to the opportunity to shape the discussions and decisions related to the strategic development of Heilongjiang's pharmaceutical industry."


Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, visit .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's role as Deputy Chairman Unit of Heilongjiang Medical Association, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    Company Contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-5392-5461

    CCG Investor Relations:
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417 (New York)

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Announces Fiscal Year 2010 Guidance
2. Renhuang Announces Price Increase on Shengmai Granules
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
5. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
6. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
7. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
10. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
11. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
Post Your Comments:
(Date:11/24/2015)... -- Avery Biomedical Devices (ABD), manufacturer of the Avery ... of Anders Jonzon , MD; Ph.D. as clinical ... Dr. Jonzon is a Physiologist and consultant in ... Uppsala and Children,s Hospital, Karolinska, Stockholm, Sweden ... the Cardiovascular Institute (UCSF). His research has covered circulation, ...
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
(Date:11/24/2015)... 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... Services, Education and Human Resources will be presenting in the ... Health Plan Strategies for a Dynamic Market" on Dec. 1, ... a consultant with the Cambridge Advisory Group, where she leads ... The webinar will discuss the rapid growth of oral ...
Breaking Medicine Technology:
(Date:11/24/2015)... N.J. (PRWEB) , ... November 25, 2015 , ... ... delivery technologies and development solutions for drugs, biologics, consumer health and global clinical ... will present at the upcoming Clinical Trial Supply East Asia Conference, to be ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress ... the developer of renewable energy technologies capable of producing commercially useful amounts of ... that its WET™ and HHT™ Boiler System reactor core modules were presented to ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... Marne, MI (PRWEB) , ... November 24, 2015 , ... ... has released a series of recent video interviews with some of the staff members ... life at the residential treatment facility, as well as some of the things that ...
Breaking Medicine News(10 mins):